PSP PRO gives brand managers an independent and unbiased assessment of how well their program satisfies patients, compared to the competition.
Livingston, NJ (PRWEB) July 28, 2016
Zitter Health Insights, a business intelligence company focused on issues of access for life sciences, pharmacy, and managed care companies, today launched Patient Support Program PRO (PSP PRO), the industry’s first independent assessment of the patient support programs used by millions of pharmaceutical and biotech consumers with chronic or ongoing medication needs.
PSP PRO is a syndicated report that measures standardized key performance indicators across multiple product brands in a selected therapeutic area. Patients evaluate their overall satisfaction with their brand’s support program, and provide specific reviews of program elements such as the enrollment hassle factor, the effectiveness and emotional impact of financial and telephone support services, and whether welcome materials are reassuring or overwhelming. The report also uncovers reasons why some program services go unused.
“In recent years, drug manufacturers have invested heavily in building more, and more robust patient support programs, but they have not had a way to objectively evaluate the program effectiveness, especially as compared to competitors,” said Yvonne Brill, Vice President New Product Development at Zitter Health Insights. “PSP PRO gives brand managers an independent and unbiased assessment of how well their program satisfies patients compared to the competition, pinpoints areas for improvement, and identifies the support services that are most valued and needed by patients.”
Pharmaceutical and biotech companies typically offer support programs to patients with chronic or ongoing conditions that require long-term medication support. The programs have been adopted to improve the patient experience, help ensure that patients obtain access to the therapy, correctly use the therapy, and continue to stay on therapy throughout all stages of the disease progression.
PSP PRO delivers comparative performance data, benchmarking multiple brands in the same therapeutic area. Typically, the reports feature the most dominant brands in each therapy area, but subscribers can request specific brands for inclusion. Zitter Health Insights can also customize and create special category reports, for unique situations such as rare therapies and new product launches.
Brand managers use PSP PRO to optimize their support program designs and thereby maximize the value patients receive from the brand’s multimillion dollar program investments. Results can also be used to validate the ROI of the program by measuring how effectively the program reduces patient calls and visits to physicians, improves adherence, and creates a positive patient experience.
PSP PRO is launching with multiple therapeutic area reports and will continue to add additional therapy area reports over the next six months. For more information or to purchase a Patient Support Program PRO report, please contact: media(at)zitter(dot)com.
Zitter Health Insights (ZHI) is a business intelligence company that offers insights to the life science and pharmacy industries on issues of access related to patients, providers, payers and pharmacies. ZHI provides syndicated research and business intelligence tools to support strategic decision making and marketing in pharmaceutical, biotech and medical products companies, along with payers, physicians, practice managers, hospitals, specialty pharmacies, pharmacy benefit managers, and other healthcare stakeholders.